Bellevue Asset Management’s PTC Therapeutics PTCT Stock Holding History

Bellevue Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-52	Closed	-$2.11K	–	473
2023 Q2	$2.11K	Hold	52	–	–	﹤0.01%	402
2023 Q1	$2.52K	Hold	52	–	–	﹤0.01%	383
2022 Q4	$1.93K	Hold	52	–	–	﹤0.01%	404
2022 Q3	$3K	Hold	52	–	–	﹤0.01%	364
2022 Q2	$2K	Hold	52	–	–	﹤0.01%	428
2022 Q1	$2K	Sell	52 -14	-21%	-$539	﹤0.01%	471
2021 Q4	$3K	Sell	66 -6	-8%	-$230	﹤0.01%	457
2021 Q3	$3K	Hold	72	–	–	﹤0.01%	474
2021 Q2	$3K	Sell	72 -8	-10%	-$343	﹤0.01%	465
2021 Q1	$4K	Sell	80 -6	-7%	-$356	﹤0.01%	471
2020 Q4	$5K	Sell	86 -19	-18%	-$1.12K	﹤0.01%	431
2020 Q3	$5K	Hold	105	–	–	﹤0.01%	399
2020 Q2	$5K	Hold	105	–	–	0.01%	400
2020 Q1	$6K	Buy	105 +51	+94%	+$2.57K	0.01%	374
2019 Q4	$3K	Buy	+54	New	+$2.29K	﹤0.01%	399

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bellevue Asset Management's PTCT Position: Q3 2023 in Review

Bellevue Asset Management sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 52 shares — an estimated $2.11K sold.

Bellevue Asset Management first reported a position in PTCT in Q4 2019 and held it in 15 quarters. The position peaked at $6K in Q1 2020. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

Bellevue Asset Management reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
Bellevue Asset Management sold 52 PTC Therapeutics shares in Q3 2023, an estimated $2.11K.
Bellevue Asset Management first reported a position in PTC Therapeutics in Q4 2019 and held it in 15 quarters.
Bellevue Asset Management's PTC Therapeutics position peaked at $6K in Q1 2020.
179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Bellevue Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.